NCT02802631View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

February 8, 2018

Study Completion Date

February 8, 2018

Conditions

Normal Healthy Volunteers

Interventions

DRUG

Minocin (minocycline) for Injection

Intravenous formulation of minocycline, a derivative of tetracycline

OTHER

Placebo

Placebo - Normal Saline

Trial Locations (1)

9713

QPS, Groningen

All Listed Sponsors

collaborator

Universitätsklinikum Köln

OTHER

collaborator

Innovative Medicines Initiative

OTHER

lead

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

INDUSTRY

NCT02802631 - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults | Biotech Hunter | Biotech Hunter